Skip links

Research

Scientific discovery at the core of our immunotherapy platform.

Science in our company

Mechanism of Action: Carbonic Anhydrase IX (CA IX) as a Therapeutic Target

At MABPRO, a.s., we focus on targeting Carbonic Anhydrase IX (CA IX), a well-characterized marker of tumor hypoxia. Hypoxia is a hallmark of aggressive tumors and contributes to therapy resistance. CA IX plays a crucial role in helping tumor cells survive in this hostile environment. By disrupting this mechanism, our therapies selectively attack the most resilient cancer cells.

Learn more

We have developed two humanized monoclonal antibodies (CA9hu-1 and CA9hu-2), each tailored for specific oncological use-cases. These assets have shown strong efficacy in preclinical models, and we are currently preparing for Phase I clinical trials.

Our scientific strategy is driven by data, with a focus on real-world translational potential and clear therapeutic benefit.

We use, among others, tumor organoid technology in our research activities. Tumor organoids are self-organized miniature tissues recapitulating the structure and functionality of the original tissue. Tumor organoids created directly from the patient’s tumor tissue represent the next step in personalized and tailor-made tumor therapy. Tumor organoids not only retain the mutational load and characteristic properties of tumor tissue, but can also simulate cellular heterogeneity and the tumor microenvironment.

Our platform integrates targeted therapies with companion diagnostics, enabling patient stratification based on the molecular profile of their tumor. This approach ensures a personalized treatment strategy, increasing the likelihood of clinical success and improving outcomes for patients with limited therapeutic options.

MABPRO, a.s. holds a comprehensive IP portfolio covering CA IX-based therapies. This includes both proprietary patents and an exclusive license to the foundational therapeutic CA IX IP developed by the Slovak Academy of Sciences. We actively collaborate with academic institutions and global biotech partners to advance the field of tumor-targeted immunotherapy.

Endometriosis – Our company’s research activities are focused not only on tumors, but also on non-tumor diseases associated with hypoxia, where the CA IX protein is present. Endometriosis is one of these diseases. It is a chronic estrogen-dependent and often very painful disease that significantly affects a woman’s quality of life. Endometrial tissue and endometriosis exhibit many of the characteristic features associated with cancer, where the microenvironment plays a key role. One of the basic features of the endometriosis microenvironment is hypoxia, which arises as a result of an imbalance between the supply and consumption of oxygen in the growing endometriotic tissue. We have also proven the presence of hypoxia and the CA IX protein in endometriosis tissue.

Cardiovascular diseases – Abdominal aortic aneurysm disease is a life-threatening, chronic degenerative condition, predominantly of the infrarenal segment of the abdominal aorta. A growing body of evidence links hypoxia and HIF-1α expression/activity to abdominal aortic aneurysm disease development/rupture. We prove the presence of hypoxia-related proteins CA IX and HIF-1α in abdominal aortic aneurysms tissues and elevated soluble CA IX concentrations in abdominal aortic aneurysms patient plasma specimens. Our results open a new window to understand and to clarify the role of CA IX in diseases associated with decreased oxygen levels in the cellular microenvironment. CA IX and the mechanisms responsible for its increase could become potential targets of future therapeutic interventions in patients with abdominal aortic aneurysm.

Our team brings together biotech entrepreneurs, immunology experts, and translational researchers. Through strategic alliances and scientific collaborations, we ensure that our work remains grounded in cutting-edge science and aligned with patient needs.

Cancer Immunotherapy Platform For Hypoxic Tumors

Where Science Meets Innovation

Our Target Mechanism For Treating Hypoxic Tumors: Carbonic Anhydrase IX (CA IX)

Targeting Carbonic Anhydrase IX (CA IX), a key marker of tumor hypoxia, offers a promising strategy against aggressive, treatment-resistant cancers. CA IX helps cancer cells adapt to low-oxygen environments, promoting their survival. By blocking this mechanism, our therapies selectively disrupt the most resilient tumor populations.

Learn more

  • Carbonic anhydrase IX (CA IX) is a cell surface protein and the most widely expressed gene in response to low tissue oxygenation, i.e. hypoxia.
  • It plays a crucial role in the removal of metabolic acids from the intracellular space and intracellular pH maintenance in order to secure cell survival.
  • At the same time, it contributes to the acidification of the pericellular milieu, which further suppresses the natural immune system response to cancer cells.

  • CA IX is the best marker of hypoxic tumors
  • The level of CA IX increases in response to hypoxia, which is a key factor of cancer progression and metastasis in a broad range of solid tumors.
  • CA IX can be detected in various types of tumors, including carcinomas of breast, kidney, pancreas, lung, head & neck, brain, and is strongly correlated with therapeutic resistance.

  • CA IX was originally discovered and characterized by the Institute of Virology of the Slovak Academy of Sciences (IV-SAS).
  • IV-SAS is the leading global center of expertise on CA IX, with close contacts to other outstanding research centers around the world focusing on the topic
  • Our team includes two of of the co-discoverers of CA IX, including the former Director of IV-SAS (Jaromir Pastorek) and the current director of the parent entity of IV-SAS, Biomedical Research Center of the Slovak Academy of Sciences (Silvia Pastorekova).

Scientific Publications

Explore our key publications in detail

Our research is rooted in rigorous scientific methodology and supported by peer-reviewed publications. We work closely with top academic institutions and experts in tumor biology, immunotherapy, and cancer mechanisms linked to hypoxia. This section presents the scientific principles that underpin our technology and therapeutic strategy.

By Category

Dlhodobý strategický výskum prevencie, intervencie a mechanizmov obezity

Learn more about our mission, science, and investment potential in our company pitch deck.

Personalized immunotherapy for hypoxic tumors

Find Out More